Statin intolerance: how common is it and how do we work with patients to overcome it?
- PMID: 35325103
- DOI: 10.1093/eurheartj/ehac156
Statin intolerance: how common is it and how do we work with patients to overcome it?
Conflict of interest statement
Conflict of interest: C.P.C. has received research grants from: Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Bristol-Myers Squibb (BMS), Daiichi Sankyo, Janssen, Merck, Novo Nordisk, and Pfizer; and consulting fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BI, BMS, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi. He serves on Data and Safety Monitoring Boards for the Veteran’s Administration, Applied Therapeutics, and NovoNordisk.
Comment on
-
Prevalence of statin intolerance: a meta-analysis.Eur Heart J. 2022 Sep 7;43(34):3213-3223. doi: 10.1093/eurheartj/ehac015. Eur Heart J. 2022. PMID: 35169843 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical